Tislelizumab before surgery for esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a single immunotherapy drug (tislelizumab) given before surgery for a type of esophageal cancer called squamous cell carcinoma. The goal is to see if it can shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a specific type of esophageal cancer (squamous cell carcinoma) that has not spread widely and can be removed with surgery.
- You have not had any prior cancer treatments, including surgery, chemotherapy, radiation, or immunotherapy.
- You are in good overall health (able to do daily activities, with adequate blood counts and organ function).
- You are willing to use effective birth control during and for 24 weeks after the study if you could become pregnant or get someone pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding the immunotherapy drug tislelizumab to standard chemotherapy before surgery or radiation can improve outcomes for people with resectable esophageal squamous cell carcinoma. It is designed for patients whose cancer is in the chest and has not spread to distant organs.
This trial tests a combination of treatments given before surgery to shrink tumors in patients with esophageal cancer that is considered too advanced for immediate surgery. The goal is to make surgery possible and improve outcomes.
This trial tests a combination of an immunotherapy drug (tislelizumab) with standard chemotherapy given before and after surgery for esophageal cancer. It aims to see if this approach can improve treatment outcomes for patients with a certain stage of the disease.
This trial tests whether giving tislelizumab (an immunotherapy) along with chemotherapy before and after surgery can help people with a type of esophageal cancer called squamous cell carcinoma. The goal is to see if this combination improves outcomes for patients whose cancer is in the chest and can be removed with surgery.
This trial tests whether adding the immunotherapy drug tislelizumab to standard chemotherapy after surgery can help prevent esophageal cancer from coming back. It is for people whose cancer had spread to lymph nodes at the time of surgery.
This trial tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy and radiation, followed by surgery, for people with advanced esophageal cancer that cannot be removed right away. It aims to see if this approach can help shrink the tumor enough to allow surgery.
Hear when a new Esophagus Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.